Response to RRx-001 in SCLC is positively correlated with a reduction in CD206(+) HLA-DR(-/low) myeloid-derived suppressor cells

by EpicentRx | Oct 28, 2021 | Journal Publications

AACR Annual Meeting 2019. Atlanta, GA, March 29th – Apr 3rd, 2019.

EpicentRx Announces Completion of First Cohort in Phase 1 “BETA PRIME” Trial with AdAPT-001

by EpicentRx | Sep 29, 2021 | 2021, Press Releases

Cancer-targeting adenovirus enhanced with a TGFβ Trap well tolerated in patients with advanced cancer Torrey Pines, Calif., Sept. 29, 2021- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today announced...

EMBO Workshop “The inflammasomes: The next frontier” 2021

by EpicentRx | Sep 21, 2021 | Conferences

September 2021, Martinsried, Germany Abstract: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model...

Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development

by EpicentRx | May 27, 2021 | Media

TGFβ for Immuno-Oncology Drug Development Conference 2021

by EpicentRx | Jan 18, 2021 | Conferences

January 2021, Virtual Poster: AdAPT-001, a replication competent type 5 adenovirus carrying a TGF-β “trap”, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model